Long-Term Therapy with Deferiprone

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 37-48

  Olivieri, Nancy F ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Deferiprone; Deferoxamine; Hepatic iron stores; Iron overload; Iron chelating therapy; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON;

AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; CANADA; CLINICAL TRIAL; DRUG EFFICACY; DRUG LEGISLATION; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; IRON OVERLOAD; ITALY; NAUSEA; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; RISK; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THALASSEMIA MAJOR; UNITED STATES; ZINC DEFICIENCY;

ANIMALS; BLOOD TRANSFUSION; CLINICAL TRIALS; DRUG APPROVAL; HEMOSIDEROSIS; HUMANS; IRON; IRON CHELATING AGENTS; PYRIDONES; THALASSEMIA; TIME FACTORS;

EID: 0030058376     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203854     Document Type: Article

References (90)

1. Baro M, Flynn D, Letsky E, Risdon RA: Long term chelation therapy in thalassemia major: Effect on liver iron concentration, liver histology and clinical progress. Br Med J 1974;ii: 16— 24.
2. Cohen AR, Martin M, Schwartz E: Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984;58:369-373.
3. Wolfe LC, Olivieri NF, Sallan DL, Propper RD, Freedman MH. Nathan DG: The prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-1603.
4. De Sanctis V, Zurlo MG, Senesi E. Boffa C, Cavallo L, Di Gregorio F: Insulin-dependent diabetes in thalassemia. Arch Dis Child 1988; 63:58-62.
5. Freeman AP, Giles RW, Berdoukas VA, Talley PA. Murray IP: Sustained normalization of cardiac function by chelation therapy in thalassemia major. Clin Lab Haematol 1989; 11:299-307.
6. Zurlo MF, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Buratini MG, Terzoli S, Gabutti V: Survival and causes of death in thalassemia major. Lancet 1989;i:27—30.
7. Bronspiegel-Weintrob N, Olivieri NF. Tyler BJ. Andrews DF. Freedman MH, Holland FJ: Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 1990;323:713-719.
8. Aldouri M, Wonke B, Hoffbrand AV, Flynn DM. Ward SE, Agnew JE, Hilson AJW: High incidence of cardiomyopathy in beta-thalas-semia patients receiving transfusion and iron chelation: Reversal by intensified chelation. Acta Haematol 1990:84:113-117.
9. Ehlers KH, Giardina PJ. Lesser ML, Engle MA, Hilgartner MW: Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-545.
10. Lcmer N, Blei F, Bieman F, Johnson L, Pio-melli S: Chelation therapy and cardiac status in older patients with thalassemia major. Am J Pediatr Hematol Oncol 1990;12:56-60.
11. Fosburg M, Nathan DG: Treatment of Cooley’s anemia. Blood 1990;76:435-444.
12. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE. Young NS. Tucker EE. Allen CJ. Farrell DE. Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
13. Olivieri NF, Nathan DG, MacMillan JH, Wayne A, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous (3 thalassemia). N Engl J Med 1994:331:574-578.
14. Cohen AR: Iron overload in the pediatric patient; in Oski FA (ed): Paediatric Hematology. Philadelphia, Saunders, 1987, pp 521-544.
15. Brittenham GM: Development of iron-chelat-ing agents for clinical use. Blood 1992:80:569— 574.
16. Olivieri NF. Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N. Logan W. Mitchell D. Ricci G. Skarf B, Freedman MH: Visual and auditory neurotoxicity in patients receiving deferoxamine infusions. N Engl J Med 1986;314: 869-873.
17. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Padda G, Fodde M, Piratsu GF, Cao A: Defcroxamine-induccd growth retardation in patients with thalassemia major. J Pediatr 1988; 113:661 — 669.
18. Porter JB, Huehns R: The toxic effects of des-ferrioxaminc. Clin Haematol 1989:2:459-474.
19. Freedman MH, Grisaru D, Olivieri NF, Mac-Lusky I, Thomer PS: Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child 1990;144:565-569.
20. Olivieri NF, Harris J. Koren G, Khattak S, Freedman MH. Templeton DM, Bailey JD, Reilly BJ: Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48-56.
21. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF: The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Haematol 1992;54:371-375.
22. Hartkamp MJ, Babyn PS, Olivieri NF: Spinal deformities in dcferoxamine-treated beta-thal-assemia major patients. Pediatr Radiol 1993; 23:525-528.
23. Third NIH-Sponsored Symposium on the Development of Iron Chelators for Clinical Use. Gainesville. May 1992.
24. Hider RC, Kontoghiorghes GJ, Silver J: UK patent GB-2118176,1982.
25. Kontoghiorghes GJ: The study of iron mobilization from transferrin using a-ketohydroxy heteroaromatic chelators. Biochim Biophys Acta 1986;869:141-146.
26. Kontoghiorghes GJ: Iron mobilization from ferritin using oxohydroxy heteroaromatic chelators. Biochem J 1986;233:299-302.
27. Porter JB, Morgan J, Hoyes KP. Burke LC, Huehns ER, Hider RC: Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 1990;76:2389— 2396.
28. Kontoghiorghes GJ: New orally active iron chelators. Lancet 1985;i:817.
29. Kontoghiorghes GJ. Hoffbrand AV: Orally active a-ketohydroxypyridine iron chelators intended for clinical use: In vivo studies in rabbits. Br J Haematol 1986:62:607—613.
30. Venkataram S, Rahman YE: Studies of an oral iron chelator: l,2-dimcthyl-3-hydroxyprid-4-one. I. Iron excretion in rats: Development of a new rapid microwave method for iron analysis in faeces. Br J Haematol 1990;75:274-277.
31. Hersko C, Link G, Pinson A, Avramovici-Gris-aru S, Sarei S, Peter HH, Hider RC, Grady RW: New orally effective iron chelators: Animal s'.udies. Ann NY Acad Sci 1990;612:351 —360.
32. Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC: Comparison of the subacute toxicity and efficacy of 3-hydroxypv-ridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991:78:2727-2734.
33. Zevin S. Link G. Grady RW, Hider RC, Peter HH, Hershko C: Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral iron chelators: Studies in hypertransfuscd rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood 1992; 79:248-253.
34. Bergeron RJ, Streiff RR. Weigand J. Luchetta G, Creary EA. Peter HH: A comparison of the iron-clearing properties of l,2-dimcthyl-3-hy-droxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992;79: 1882-1890.
35. Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV: l,2-dimcthyl-3-hydroxy-pyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;i: 1294— 1295.
36. Kontoghiorghes GJ: Effective chelation of iron in thalassemia with the oral chelator 1,2-dime:hyl-3-hydroxypyrid-4-onc. Br Med J 1987;295:1509-1512.
37. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy AR, Hirt A. Hoffbrand AV, Lottenbach AM. Sondsregger T. Wagner HP: LI (1.2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassemia major. Br J Haematol 1990;76:550-533.
38. Agarwal MB, Viswanathan C, Ramanathan J, Massil DE, Shah S. Supte SS. Vasandani D, Puniyani RR: Oral iron chelation with LI. Lancet 1990,335:601.
39. Olivieri NF, Koren G, Hermann C, Bentur Y. Chung D, Klein J, St Louis P, Freedman MH. McClelland RA, Templeton DM: Comparison of oral iron chelator LI and desferrioxamine in iron-loaded patients. Lancet 1990,336:1275-1279.
40. Collins AF, Fassos FF, Stobie SS, Lewis N, Shaw D, Fernandes D, Fry M, Templeton DM, Koren G, Olivieri NF: Iron balance and dose response studies of the oral iron chelator 1.2-dimcthyl-3-hydroxypyrid-4-one (LI) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-2333.
41. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J. Nortey P: Long-term trial with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4-one (LI). Br J Haematol 1990;76:295-304.
42. Al-Refaic FN. Wonke B, Hoffbrand AV, Wick-ens DG, Nortey P. Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral iron chclator l,2-dimcthyl-3-hydroxypyrid-4-one(Ll) in thalassemia major. Blood 1992:80: 592-599.
43. Agarwal MB. Gupte SS, Viswanathan C, Vas-andani D. Ramanathan J, Desai N, Puniyani RR. Chhablani AT: Long-term assessment of efficacy and safety of LI, and oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466.
44. Olivieri NF. Brittenham GM, Matsui D. Bcr-kovitch M, Blcndis LM, Cameron RG, McClelland RA, Liu PP. Templeton DM, Koren G: Iron-chclation therapy with oral defcripronc in patients with thalassemia major. N Engl J Med 1995;332:918-922.
45. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrel DE, Harris JW: Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993:42:81— 85.
46. Olivieri NF, Koren G, Matsui D, Liu PP, Blcndis L, Cameron R, McClelland RA, Templeton DM: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chclator LI in thalassemia intermedia. Blood 1992;79:2741-2748.
47. Engle MA, Erlandson M, Smith CH: Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964;30:698-705.
48. Link G, Pinson A, Hershko C: Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-onc and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994:83: 2692-2697.
49. Fitchett DH, Coltart DJ, Llittlcr WA, Lcyland MJ, Trueman T, Gozzard G, Peters TI: Cardiac involvement in secondary haemochroma-tosis: A catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14:719— 724.
50. Johston DL, Liu PP: Evaluation of myocardial ischemia and infarction by nuclear magnetic resonance techniques. Can J Cardiol 1988;4: 116-120.
51. Frahm J, Hasse A, Matthaei D: Rapid 3-dimensional MR imaging using the FLASH techniques. J Comput Assist Tomogr 1986,10: 363.
52. Olivieri NF. Bcluzzo N, Muraca M, MacKen-zie CC, Polsinclli K, Korean G. Liu PP, Brittenham GM: Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassemia major during long-term therapy with the orally active iron chelating agent LI. Blood 1994;84(suppl l):109a.
53. Fujisawa I, Morikawa M. Nakano Y, Komishi J: Hemochromatosis of the pituitary gland: MR imaging. Radiology 1988;168:213-214.
54. Hcrshko C, Graham G, Bates GW, Rachmile-witz EA: Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. BrJ Haematol 1978:40:255— 263.
55. Grootveld M, Bell JD, Halliwcll B, Aruoma OI, Bomford A, Sadler PJ: Non-transferrin-bound-iron in plasma or scrum from patients with idiopathic hemochromatosis. J Biol Chcm 1989;264:4417-4422.
56. Halliwell B. Gutteridge JMC: Oxygen, free radicals and iron in relation to biology and medicine: Some problems and concepts. Arch Biochem Biophys 1986;246:501-514.
57. al-Refaie FN, Wickcns DG. Wonke B. Kon-toghiorghcs GJ, Hoffbrand AV: Serum non-transferrin-bound iron in beta-thalassacmia major patients treated with desferrioxamine and LI. BrJ Haematol 1992;82:431-436.
58. Olivieri NF, Sher GD, MacKinnon JA, Pope E, Entsuah B. Snider M, Lewis N, Shaw D, Koren G, Brittenham GM: The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chclating agent LI. Blood 1994:84(suppl l):363a.
59. Kontoghiorghes GJ: Design, properties, and effective use of the oral chelator LI and other a-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia. Ann NY Acad Sci 1990:612:339-350.
60. Porter JB, Hoyes KP, Abeysinghe R, Huehns ER, Hider RC: Animal toxicology of iron chelator LI. Lancet 1989;ii: 156.
61. Biesemeier JA, Laveglia J: 14-day oral toxicity study in dogs with l,2-dimethyl-3-hydroxypy-rid-4-one (DMHP, LI). Waverly, Food and Drug Research Laboratories, Contract No NOl-DK-4-2255, N1DDK, NIH, 1991.
62. Bcrkoukas VA, Bentley P. Frost H, Schnebli HP: Toxicity of oral iron chclator LI. Lancet 1993;341:1088.
63. al-Refaie FN, Hershko C, Hoffbrand AV, Ko-saryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term dcferiprone (LI) therapy: A report by the International Study Group on Oral Iron Chelators, submitted.
64. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF: Arthropathy in thalassemia patients receiving deferi-prone. Lancet 1994;343:1471-1472.
65. Hershko C, Link G, Pinson A, Peter HH, Dobbin P. Hider RC: Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cclls in culture. Blood 1991;77:2049-2053.
66. Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JMC: The importance of iron in rheumatoid disease. Lancct 1981:ii: 1142-1144.
67. Gratwick GM, Bullough PG, Bohne WHO, Markcnson AL, Peterson CM: Thalassemic osteoarthropathy. Ann Intern Med 1978:88:494— 501.
68. Hoffbrand AV, Bartlett AN, Veys PP, O’Connor NTJ, Kontoghiorghes GJ: Agranulocytosis and thrombocytopenia in a patient with Black-fan-Diamond anaemia during oral chclator trial. Lancet 1989;ii:457—458.
69. Goudsmit R, Kerstcn MJ: Longterm treatment of transfusion hemosiderosis with the oral chelator LI. Drugs Today 1992; 28(suppl A): 133— 135.
70. Agarwal MB. Gupte SS, Viswanathan C, Vas-andani D, Dcsai N, Chablani AT: Long term efficacy and toxicity of Ll-oral chclator in transfusion dependent thalassemics over the last three years (abstract). 5th Int Conf on Thal-assaemias and Hacmoglobinopathies. Nicosia. 1993, p 192.
71. al-Refaie FN, Wonke B, Hoffbrand AV: Defer-ipronc-associated myelotoxicity. Eur J Haematol 1994;53:298-301.
72. Hoffbrand AV: Prospccts for oral iron chelation:herapy. J Lab Clin Med 1994; 123:492— 494.
73. Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB: In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hematopoiesis. Exp Haematol 1993;21:86-92.
74. Cunningham JM, al-Refaie FN, Hunter AE. Sheppard LN, Hoffbrand AV: Differential toxicity of a-kctohydroxypyridinonc iron chelators and desfcrrioxamine to human haemo-poietic precursors in vitro. Eur J Haematol 1994.52:176-179.
75. Mehta J, Singhal S, Chablani A, Revankar R, Walvalkar A: Ll-induced systemic lupus erythematosus. Indian J Hematol Blood Transfus 1991.9:33-37.
76. Mehta J. Singhal S, Revankar R, Walvalkar A. Chablani A, Mehta BC: Fatal systemic lupus erythematosus in patient taking oral iron chelator LI. Lancet 1991:337:298.
77. Patlanapanyasat K, Webster HK, Tongtawa P, Kongcharocn P, Hider RC: Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function. Br J Haematol 1992:82:431-436.
78. Grady RW. Srinivasan R. Dunn JB. Courscy MP, Lemert RF, Calvano SE, Hilgartner MW: Evidence of toxicity due to 1.2-dimethyl-3-hydroxypyrid-4-onc (LI) in normal rats. Drugs Today 1992;28(suppl A):73-80.
79. Berkovitch M. Meydan N, Donsky J, Collins AF, Sher GD, Matsui D, Koren G, Hackman R, Roifnian C, Olivieri NF: Detailed investigations of immune function in patients (pts) receiving the iron chclator l,2-dimethyl-3-hy-droxypyrid-4-onc (LI): No evidence of abnormality after three years of therapy. Blood 1993: 81:360a.
80. al-Rcfaic FN, Wonke B. Wickens DG. Aydinok Y, Fielding A, Hoffbrand A: Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypy-rid-4-onc or desferrioxamine. J Clin Pathol 1994:47:657-660.
81. Litt I, Cuskey W: Compliance with medical regiment during adolescence. Pediatr Clin North Am 1980;27:3-15.
82. Olivieri NF, Hermann C, Matsui D, Koren G: Compliance assessed by the Mediation Event Monitoring System. Arch Dis Child 1992;66: 1399-1402.
83. Matsui D, Hermann C, Klein J, Olivieri NF, Koren G: Critical comparison of a novel and existing methods of assessment of compliance during a clinical trial of a new oral iron chelator. J Clin Pharmacol 1994;34:944-949.
84. Cramer JA, Mattson RH, Prevey ML; Scheyer RD, Ouellette VI,: How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277.
85. Basran RK, Fassos FF, Shaw D, Olivieri NF: Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent LI. Blood 1994;84(suppl 1):261 a.
86. Olivieri NF, Koren G, St Louis P, Freedman MH, McClelland RA, Templeton DM: Studies of the oral chelator 1.2-dimethyl-3-hydroxypy-rid-4-one in thalassemia patients. Semin He-matol 1990;27:101-104.
87. Matsui D, Klein J. Hermann C, Grunau V, McClelland RA. Chung D, St Louis P. Olivieri N, Koren G: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dime-thyl-3-hydroxypyrid-4-one (LI) in patients with thalassemia. Clin Pharmacol Ther 1991; 50:294-298.
88. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L: Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-261.
89. al-Refaie FN, Sheppard LN, Nortey P, Wonke B: Ho fib rand AV: Pharmacokinetics of the oral iron chelator deferiprone (LI) in patients with iron overload. Br J Haematol 1995;89:403— 408.
90. Hershko C: Development of oral iron chelator LI. Lancet 1993;241:1088-1089.